Action Mechanisms of Metformin Combined with Exenatide and Metformin Only in the Treatment of PCOS in Obese Patients

Table 1

Clinical characteristics and biochemical data between the COM and MF group.

	COM group			MF group
	Before	After	Δ (before—after)	Before	After	Δ (before—after)
Age (years)	29.96 ± 5.39	—	—	28.45 ± 4.74	—	—
BMI (kg/m^2)	32.30 ± 3.87	31.21 ± 3.86^##	1.09 ± 1.09	29.90 ± 2.66	29.37 ± 2.85^##	0.53 ± 0.80
WHR	0.91 ± 0.07	0.91 ± 0.05	0.0066 ± 0.056	0.91 ± 0.07	0.90 ± 0.07	0.0057 ± 0.036
LH (IU/L)	6.61 ± 3.52	10.54 ± 12.94	−3.93 ± 14.96	8.66 ± 5.76	10.85 ± 6.65	−2.18 ± 6.93
FSH (IU/L)	5.73 ± 2.33	55.60 ± 37.72	−1.98 ± 3.80	5.69 ± 1.97	7.37 ± 1.57	−1.67 ± 2.86
E2 (pg/ml)	7.72 ± 2.83	81.20 ± 51.07	25.60 ± 76.26	59.44 ± 34.96	53.78 ± 17.62	25.66 ± 34.12
TT (ng/ml)	0.72 ± 0.31	0.59 ± 0.21^##	0.13 ± 0.21	0.71 ± 0.22	0.55 ± 0.17^#	0.15 ± 0.20
DHAS (μg/dl)	253.39 ± 74.15	252.69 ± 88.43	0.70 ± 50.15	267.45 ± 115.39	260.30 ± 110.99	7.15 ± 47.09
FBG (mmol/L)	5.16 ± 0.59	5.02 ± 0.45	0.15 ± 0.42	5.25 ± 0.42	5.28 ± 0.45	−0.26 ± 0.30
OGTT-2h BG (mmol/L)	7.90 ± 1.44	7.40 ± 1.87	0.49 ± 2.37()	7.24 ± 1.66	8.48 ± 1.56^##	−1.24 ± 1.46
FINS (μIU/ml)	26.29 ± 14.38	22.69 ± 9.37	3.60 ± 12.18()	20.04 ± 7.15	23.53 ± 10.28	−3.47 ± 7.71
OGTT‐2h INS (μIU/ml)	198.99 ± 85.58	156.46 ± 92.59	42.53 ± 105.85	149.43 ± 67.21	131.49 ± 62.20	17.93 ± 79.25
HbA1c	5.46 ± 0.47	5.34 ± 0.42^#	0.12 ± 0.24	5.34 ± 0.32	5.31 ± 0.21	0.03 ± 0.23
HOMA-IR	6.17 ± 3.67	5.01 ± 1.94	1.16 ± 3.29 ()	4.53 ± 1.88	5.38 ± 2.56	−0.85 ± 1.84
TC (mmol/L)	4.99 ± 0.85	5.29 ± 1.06	−0.30 ± 0.87	5.19 ± 0.90	5.32 ± 0.96	−0.53 ± 0.79
TG (mmol/L)	2.09 ± 1.64	2.48 ± 0.87	−0.39 ± 1.53	2.26 ± 1.78	2.89 ± 1.60	−0.62 ± 1.91
HDL-c (mmol/L)	1.23 ± 0.32	1.43 ± 0.32^##	−0.20 ± 0.26	1.17 ± 0.20	1.46 ± 0.32^##	−0.29 ± 0.20
LDL-c (mmol/L)	3.08 ± 0.65	3.07 ± 0.85	0.007 ± 0.813	3.36 ± 0.69	3.33 ± 0.86	0.02 ± 0.76
ApoA1 (g/L)	1.38 ± 0.34	1.65 ± 0.35^##	−0.28 ± 0.34	1.28 ± 0.12	1.71 ± 0.36^##	−0.43 ± 0.31
ApoB (g/L)	1.00 ± 0.17	0.99 ± 0.18	0.006 ± 0.176	1.03 ± 0.20	1.11 ± 0.20^#	−0.082 ± 0.18
LP(a) (mg/dL)	165.86 ± 203.27	146.68 ± 203.30	19.18 ± 56.22	97.00 ± 90.44	53.00 ± 52.87^##	44.00 ± 51.81
FFA (μmol/L)	605.59 ± 219.38	647.59 ± 220.25	−42.00 ± 215.88	694.60 ± 187.18	678.25 ± 219.07	16.35 ± 295.87
hsCRP (mg/L)	5.01 ± 4.46	4.73 ± 4.27	0.28 ± 4.17	3.69 ± 2.56	3.90 ± 2.90	−0.21 ± 3.63
WBC (10^/L)	7.00 ± 1.19	7.24 ± 1.85	−0.24 ± 1.37 ()	7, 46 ± 1.17	6.81 ± 1.03^#	0.65 ± 1.01
ALT (U/L)	37.92 ± 31.01	29.32 ± 20.26	8.60 ± 19.35	32.57 ± 17.28	37.05 ± 46.09	−4.48 ± 38.16
Cr (μmol/L)	60.96 ± 9.51	59.13 ± 8.17	1.83 ± 5.68	60.33 ± 6.06	56.71 ± 7.63^#	3.62 ± 5.2

BMI, body mass index; WHR, waist-hip ratio; FBG, fasting blood glucose; TT, total testosterone; DHAS, dehydroepiandrosterone sulfate; OGTT, oral glucose tolerance test; HbA1c, hemoglobin A1C; Fins, fasting serum insulin; OGTT-2h INS, 2-hour insulin in OGTT. HOMA-IR, homeostasis model assessment-insulin resistant; TC, total Cholesterol; TG, triglycerides; HDL-c: high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; ApoA1, lipoprotein A1; ApoB, lipoprotein B; LP(a), lipoprotein-a; FFA, free fatty acid; hsCRP, high-sensitivity C-reactive protein; DC, white blood cell count; ALT, alanine aminotransferase; Cr, creatinine. Homeostasis model assessment-Insulin resistant (HOMA-IR) = fasting serum insulin (mIU/L) × fasting blood glucose (FBG, mmol/L)/22.5 [11]. Significant difference between the COM group and MF group (, ). ^#Significant increase or decrease after treatment in the COM group or MF group (^#, ^##).